First Results From Editas CRISPR Eye Therapy Underwhelm Investors
Safety Is Reassuring But Efficacy Unclear
Editas is one of a handful of biotechs developing in vivo CRISPR therapies, alongside the likes of Intellia and CRISPR Therapeutics • Source: Alamy 
